Chris Bowden, M.D.
CHIEF MEDICAL OFFICER, AGIOS PHARMACEUTICALS
Dr. Bowden, an oncology drug development executive with more than 20 years leadership experience including the approval of several cancer medicines, joined Ziopharm’s Board in October 2019. He has been the chief medical officer of Agios Pharmaceuticals since May 2014. Previously, Dr. Bowden was vice president product development oncology, at Genentech for eight years. From 2003 to 2006, he was the executive director for EMEA regions for Bristol-Myers Squibb. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, at Pharmacia Corporation and Janssen Pharmaceutical. Prior to industry, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center. Dr. Bowden received his M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.
Retired CEO, Biospecifics, TetraLogic and Cephalon
Mr. Buchi joined the Ziopharm Board in September 2020. He has deep life sciences industry experience, notably 15 years with Cephalon, including serving as its Chief Executive Officer during Cephalon’s acquisition by Teva Pharmaceuticals in 2011 for $6.8 billion. Subsequently, Mr. Buchi served as Chief Executive Officer of TertraLogic Pharmaceuticals, and more recently as Chief Executive Officer of Biospecifics Technologies, prior to his retirement. Following the acquisition of Cephalon by Teva in 2011, Mr. Buchi served as corporate vice president of global branded products at Teva. In addition, Mr. Buchi currently serves as chairman of Dicerna Pharmaceuticals, and as a director of Amneal Pharmaceuticals and Benitec Biopharma Ltd. Mr. Buchi earned a B.A. in Chemistry from Cornell University and a Master’s in Management, Accounting and Finance from the Kellogg School of Management at Northwestern University.
Heidi M. Hagen
Chief Executive Officer, Ziopharm Oncology
Ms. Hagen was appointed Interim Chief Executive Officer of Ziopharm in February 2021. She has served on the Board since June 2019 and is a 30-year veteran of the biotechnology industry, the last 20 in cell and gene therapy. Ms. Hagen is co-founder and board member of Vineti, a cloud-based software platform company that addresses challenges in data management from order through cell collection, manufacturing, and delivery of personalized treatments such as cell and gene therapies and cancer vaccines. She has extensive experience in operations management and commercializing innovative technologies. She is also the former Global COO for SOTIO a.s. and the Senior Vice President of Operations for Dendreon. Ms. Hagen has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.
Managing Partner, Kleiner Perkins Caufield & Byers China
Mr. Huang, a life sciences industry veteran entrepreneur with 20+ years’ experience, joined Ziopharm’s Board in July 2020. He is currently a Managing Partner at Kleiner Perkins Caufield & Byers (KPCB) China and has founded and financed several innovative biotech companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which formed TriArm Therapeutics, the funding partner for Ziopharm’s joint venture, Eden BioCell. Prior to joining KPCB in 2011, he was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, he led numerous investments in China. Prior to joining Vivo in 2007, Mr. Huang was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp (acquired by Johnson & Johnson). Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
Principal and Founder of WaterMill Asset Management Corporation
For over two decades, Mr. Postma has served as the principal of WaterMill Asset Management, an asset management firm which he founded that actively trades in municipal bonds and equities. Mr. Postma has valuable relationships with prospective financial partners and brings a strong ownership perspective to Ziopharm’s boardroom, as WaterMill is one of the largest, long-term shareholders of the Company. In addition, he brings over four decades of experience investing across the equity and fixed income markets and frequently analyzes, invests in and engages with healthcare and biotechnology companies. Mr. Postma holds a Bachelor of Arts degree in Business and Economics from Lafayette College.
Special Advisor for the Bill & Melinda Gates Medical Research Institute
A biotechnology leader with 25+ year track record of creating shareholder value through strategy, business development, commercial and financial leadership, Mary Thistle joined Ziopharm’s Board in November 2020. Ms. Thistle is Special Advisor for the Bill & Melinda Gates Medical Research Institute, where she previously held the role of Chief of Staff. Prior to joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics, where she directed multiple financing rounds (including the company’s IPO), expanded the pipeline through strategic business development transactions, and led the sale of the company for a significant premium. Previously, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale of the company. She has also held leadership positions at ViaCell and PerkinElmer. Ms. Thistle began her career in finance as a Certified Public Accountant, after graduating summa cum laude with a bachelor’s degree in business and accounting from the University of Massachusetts. Ms. Thistle serves on the Boards of Directors of Homology Medicines and Enterome SA.
Manager of Brushwood LLC, former Managing Partner and co-principal of Castle Hill Asset Management LLC
Jaime Vieser has over 30 years of investment management and banking experience, which includes his involvement in numerous successful corporate restructurings and providing both start-up capital and guidance for emerging technology and biotech companies.
Since 2017, Mr. Vieser has been the manager of a private investment firm, Brushwood LLC. Mr. Vieser has over three decades of experience investing across various asset classes and served for nearly a decade as Managing Partner and co-principal of Castle Hill Asset Management LLC (“Castle Hill”), a multi-billion dollar asset manager and hedge fund. Mr. Vieser has a deep understanding of Ziopharm’s assets, governance, and financials as he is a sizable and long-term shareholder of the Company. Prior to founding Castle Hill, for 10 years Mr. Vieser was responsible for the High Yield Sales and Trading Group in London at Deutsche Bank AG, a multinational investment bank and financial services company. Earlier in his career, Mr. Vieser worked as a banker in the Leveraged Finance division of Bankers Trust Company, a bank holding company that was acquired by Deutsche Bank AG in 1999. Mr. Vieser holds a Bachelor’s degree in Economics from the University of Michigan and a Master’s in Business Administration from the Cox School of Business at Southern Methodist University.
President of Weis Advisors, Inc.
Mr. Weis has served as a member of our board since December 2020. Mr. Weis serves as the principal of Weis Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018. He has also served as the Chief Financial Officer and Director of PhenoTarget Biosciences, Inc., a biotech start-up company from April 2020 to March 2021. Prior to that, he served in a number of roles at DemeRx, Inc., a clinical stage pharmaceutical company developing nonaddictive treatments for drug addiction, including serving as Chief Operating Officer and Chief Financial Officer from December 2011 to July 2017, and also as President from September 2014 to July 2017, and as a Consultant from July 2017 to April 2018. Earlier in his career, Mr. Weis served as the Chief Financial Officer of EnSA Holdings, LLC, a company that focuses on environmentally sustainable agriculture techniques and technologies for the production of rice, from August 2010 to November 2011. From 2006 to 2010, he served as the Vice President & Chief Financial Officer, Secretary and Treasurer of NovaVision, Inc., a therapeutic and diagnostic vision restoration company. Prior to that, he served as the Chief Financial Officer & Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. Weis served as a Senior Manager at Ernst & Young, a multinational professional services company, from 1986 to 2000. Mr. Weis has co-authored a number of scientific papers and presentations and is an inventor on a number of patents and patent applications. Mr. Weis received a Bachelor of Business Administration in Accounting from the University of Georgia and is a Certified Public Accountant.
The board believes that Mr. Weis’s management and industry experience, as well as his financial expertise, qualify him to serve on the board.